TCI Wealth Advisors’s Theriva Biologics TOVX Stock Holding History

TCI Wealth Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Hold	0	–	–	–	1599
2018 Q1	–	Hold	0	–	–	–	1437
2017 Q4	–	Hold	0	–	–	–	1069
2017 Q3	–	Hold	0	–	–	–	879
2017 Q2	–	Hold	0	–	–	–	1028
2017 Q1	–	Sell	-1	Closed	-$6.98K	–	980
2016 Q4	$4K	Buy	+1	New	+$10.3K	﹤0.01%	852
2016 Q3	–	Hold	0	–	–	–	661
2016 Q2	–	Sell	-1	Closed	-$18.8K	–	657
2016 Q1	$11K	Hold	1	–	–	0.01%	564
2015 Q4	$11K	Hold	1	–	–	0.01%	568
2015 Q3	$12K	Hold	1	–	–	0.01%	483
2015 Q2	$20K	Hold	1	–	–	0.01%	407
2015 Q1	$17K	Buy	+1	New	+$17.9K	0.01%	376

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TCI Wealth Advisors's TOVX Position: Q2 2018 in Review

TCI Wealth Advisors held its Theriva Biologics (TOVX) position steady in Q2 2018 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1599.

TCI Wealth Advisors first reported a position in TOVX in Q1 2015 and has held it in 6 quarters since. The position peaked at $20K in Q2 2015. 46 funds tracked by Wall St. Rank hold TOVX as of Q2 2018.

TCI Wealth Advisors held 0 shares of Theriva Biologics worth $0 as of Q2 2018.
TCI Wealth Advisors left its Theriva Biologics share count unchanged in Q2 2018.
Theriva Biologics made up ﹤0.01% of TCI Wealth Advisors's portfolio in Q2 2018, its #1599 holding.
TCI Wealth Advisors first reported a position in Theriva Biologics in Q1 2015 and has held it in 6 quarters since.
TCI Wealth Advisors's Theriva Biologics position peaked at $20K in Q2 2015.
46 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2018.

Based on TCI Wealth Advisors's 13F filing for Q2 2018, filed 27 Jul 2018.